An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer. Data will be collected for approximately 24 months.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Patients with metastatic breast cancer in first line treatment who have completed treatment with Avastin

Exclusion Criteria:

• Patients not willing or unable to signed written consent form